Scoring tool for systemic symptoms during aspirin challenge detects mediator production in aspirin-exacerbated respiratory disease

Ann Allergy Asthma Immunol. 2021 Jul;127(1):131-133. doi: 10.1016/j.anai.2021.03.025. Epub 2021 Mar 27.

Authors

Patrick J Staso¹, Pingsheng Wu¹, Tanya M Laidlaw², Katherine N Cahill³

Affiliations

¹ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: Katherine.cahill@vumc.org.

No abstract available

Publication types

Letter
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intranasal
Adult
Aspirin / adverse effects*
Cyclooxygenase Inhibitors / administration & dosage*
Dose-Response Relationship, Drug
Drug Hypersensitivity / diagnosis
Enzyme-Linked Immunosorbent Assay
Female
Humans
Leukotrienes / analysis
Male
Nasal Lavage Fluid / chemistry
Nasal Provocation Tests / methods*
Prospective Studies
Prostaglandins / analysis
Respiratory Tract Diseases / chemically induced
Respiratory Tract Diseases / diagnosis*
Severity of Illness Index

Substances

Cyclooxygenase Inhibitors
Leukotrienes
Prostaglandins
Aspirin

Associated data

ClinicalTrials.gov/NCT02824523

Grants and funding